Vaniprevir
 | |
| Names | |
|---|---|
| IUPAC name
(1R,21S,24S)-21-tert-butyl-N-((1R,2R)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-ethylcyclopropyl)-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]-heptacosa-6,8,10-triene-24-carboxamide | |
| Identifiers | |
| 923590-37-8 | |
| 3D model (Jmol) | Interactive image |
| ChEMBL | ChEMBL599872 |
| ChemSpider | 24651717 |
| ECHA InfoCard | 100.207.830 |
| UNII | CV3X74AO1H  |
| |
| Properties | |
| C38H53N5O9S | |
| Molar mass | 755.9 g/mol |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4a protease inhibitor, developed by Merck & Co., which is currently in clinical testing.[1]
In Japan, it was approved for treating hepatitis C in 2014.[2][3]
References
- ↑ McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, Gilbert KF, Bush KJ, Holloway MK, Swestock J, Wan BL, Carroll SS, DiMuzio JM, Graham DJ, Ludmerer SW, Mao SS, Stahlhut MW, Fandozzi CM, Trainor N, Olsen DB, Vacca JP, Liverton NJ (March 2010). "Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor". J. Med. Chem. 53 (6): 2443–63. doi:10.1021/jm9015526. PMID 20163176.
- ↑ "First recommendation for HCV drug vaniprevir, in Japan". datamonitorhealthcare.com. September 25, 2014.
- ↑ "New Drugs Approved" (PDF). Pharmaceuticals and Medical Devices Agency.
This article is issued from Wikipedia - version of the 5/25/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.